Published in final edited form as:

J Proteomics Bioinform. 2012 January 30; 5(2): . doi:10.4172/jpb.1000210.

Transcriptomic Profiling of Medial Temporal Lobe Epilepsy

Abhilash K. Venugopal^{1,2,3,4}, Ghantasala S. Sameer Kumar^{1,2}, Anita Mahadevan⁵, Lakshmi Dhevi N. Selvan^{1,6}, Arivusudar Marimuthu^{1,7}, Jyoti Bajpai Dikshit⁸, Pramila Tata⁸, YL Ramachandra², Raghothama Chaerkady^{1,2,3,4}, Sanjib Sinha⁹, BA Chandramouli¹⁰, A Arivazhagan¹⁰, Parthasarathy Satishchandra^{9,*}, SK Shankar⁵, and Akhilesh Pandey^{3,4,11,12,*}

¹Institute of Bioinformatics, International Technology Park, Bangalore, India

²Department of Biotechnology, Kuvempu University, Shimoga, India

³McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

⁴Departments of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

⁵Department of Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, India

⁶School of Biotechnology, Amrita University Kollam 690525, India

⁷Manipal University, Madhav Nagar, Manipal, Karnataka 576104, India

⁸Strand Life Sciences, Bangalore, India

⁹Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India

¹⁰Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Bangalore, India

¹¹Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

¹²Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Abstract

Epilepsy is one of the most prevalent neurological disorders affecting ~1% of the population. Medial temporal lobe epilepsy (MTLE) is the most frequent type of epilepsy observed in adults who do not respond to pharmacological treatment. The reason for intractability in these patients has not been systematically studied. Further, no markers are available that can predict the subset of patients who will not respond to pharmacotherapy. To identify potential biomarkers of epileptogenicity, we compared the mRNA profiles of surgically resected tissue from seizure zones with non-seizure zones from cases of intractable MTLE. We identified 413 genes that exhibited 2-fold change that were statistically significant across these two groups. Several of these

Copyright: © 2012 Venugopal AK, et al.

*Corresponding authors: Akhilesh Pandey, MD, Ph.D, McKusick-Nathans Institute of Genetic Medicine, 733 N. Broadway, BRB 527, Johns Hopkins University, Baltimore, USA, Tel. 410-502-6662; Fax: 410-502-7544; pandey@jhmi.edu. Dr. Satishchandra P, MD, DM, Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India, Tel: 91-080-26995001/5002; Fax 91-080-26564830; satishchandra@nimhans.kar.nic.in.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Supplementary Information

The complete list of differential expressed genes (p value < 0.05) with a fold value of 2 is provided in the supplementary Table 1.

differentially expressed genes have not been previously described in the context of MTLE including claudin 11 (*CLDN11*) and bone morphogenetic protein receptor, type IB (*BMPRI1B*). In addition, we found significant downregulation of a subset of gamma-aminobutyric acid (GABA) associated genes. We also identified molecules such as *BACH2* and *ADAMTS15*, which are already known to be associated with epilepsy. We validated one upregulated molecule, serine/threonine kinase 31 (*STK31*) and one downregulated molecule, SMARCA4, by immunohistochemical labeling of tissue sections. These molecules need to be further confirmed in large-scale studies to determine their potential use as diagnostic as well as prognostic markers in intractable MTLE.

Keywords

Transcriptome profile; DNA microarrays; Temporal lobe epilepsy; GeneSpring; Medial temporal sclerosis; GABA receptor

Introduction

An epileptic seizure is a sudden, highly synchronized, electrical discharge of neurons in virtually any cortical area of the brain that disrupts normal functioning of the brain. According to World Health Organization estimates, the number of epilepsy cases worldwide is 8.9 per 1,000 individuals, thus affecting ~ 60 million people [1]. Medial temporal lobe epilepsy (MTLE) is the most frequent form of partial epilepsy observed in adults, accounting for 40% of cases. About 30% of MTLE cases are resistant to anti-epileptic drugs [2–4]. Intractable MTLE corroborates with an underlying pathology in the medial temporal lobe, most often with Ammon's horn sclerosis (AHS) [5,6]. Prediction, or even early identification of intractability, could help plan better clinical management of patients by combined drug therapy and surgery to achieve an effective remission [4]. However, the biology of drug resistance is poorly understood and there are no biomarkers to predict the subset of patients who are going to develop intractable epilepsy.

Most of the drugs used in epilepsy are based on research conducted on acute seizure models in animals [6]. There are a limited number of studies [7–13] that have investigated temporal lobe epilepsy using microarrays. However, these studies were limited in that they used animal models as experimental subjects [13] and used older technologies such as cDNA microarrays containing only a small fraction of the human transcriptome [10]. Jamali et al. [10] studied surgically resected epileptogenic zones from entorhinal cortex using cDNA arrays. Van Gassen et al. [11] compared sclerotic hippocampus to nonsclerotic hippocampus from MTLE cases. Integration of ten published datasets from ten refractory epilepsy studies resulted in only a small number of genes that were consistent across multiple studies [14]. This shows the necessity of additional studies at the whole human genome level to identify candidate genes as biomarkers for temporal lobe epilepsy.

In the present study, to identify the genes associated with seizures, we chose to compare the transcriptome of spiking zones with non-spiking zones in patients who underwent temporal lobectomy. Spiking zones, which are the focus of ictal discharges, were identified by intraoperative surface electrocorticogram. The non-spiking zones are those regions which did not elicit any signal in the electrocorticogram, but were resected as part of the surgical resection protocol. This use of affected and non-affected tissue from the same patient also reduced the inter-individual differences that could otherwise arise from different therapeutic regimens or different genetic backgrounds. We used whole human genome oligonucleotide arrays to probe the genome wide expression changes in intractable MTLE. We identified 102 genes that were upregulated 2-fold and 311 genes that were downregulated 2-fold in affected

regions of the temporal lobe. We performed immunohistochemical validation of two novel molecules identified in this study - *STK31* and *SMARCA4*. Identification of these potential biomarkers in body fluids such as cerebro spinal fluid (CSF) from the cases of epilepsy could lead to development of improved methods of management recognizing the pathobiology and of intractable MTLE.

Materials and Methods

Patients

The patients who were diagnosed to have medically refractory epilepsy due to mesial temporal sclerosis (MTS) and underwent standard anterior temporal lobectomy (ATL) with amygdalo-hippocampectomy (AH) were included in the study. Patients had intractable complex partial seizures as defined by the occurrence of a minimum of two seizures every month despite therapy with two anti-epileptic drugs (AEDs) at maximum tolerated doses for at least two years. The patients underwent standard phase 1 pre-surgical evaluation with clinical review, routine electroencephalogram (EEG), MTS-protocol based MRI, video-EEG and neuropsychological assessment. MRI of brain demonstrated volume loss, signal changes, loss of normal architecture, loss of internal digitization of hippocampus and increased T2 relaxometry to confirm the diagnosis of MTS. Based on the concordant observations, decision for surgical resection was taken after explaining the available options and obtaining the written informed consent from the patient. Patients underwent en bloc ATL with AH. All patients underwent intra-operative surface electrocorticography from the superior, middle and inferior temporal gyri and hippocampus. The Institutional Scientific Ethics Committee approved the study and utilization of the surgically resected human brain tissue for research purposes. Ten patients fulfilled the above-mentioned criteria and tissues from those patients were employed for the study.

Tissue samples

The location of the intra-operative surface electrocorticography activity representing the spike activity and silent areas were marked on an anatomical tracing of hippocampus and medial and lateral temporal lobe areas to localize the electrical activity on the resected specimens. The specimens were sliced coronally (5 mm thick) along the whole length of the hippocampus. This slice of Ammon's horn zone and temporal lobe areas where electrical spikes were recorded and relatively silent non-spike area (Table 1) were selected and placed in RNA later (n=10). The rest of the tissues were fixed in buffered formalin and processed for histological evaluation. Representative areas of the resected specimens were histologically evaluated to confirm Ammon's horn sclerosis for inclusion in the study. Cases with dual pathology like neoplastic or vascular lesions and those with extra hippocampal pathology of glioneuronal cortical neoplasms were excluded.

For immunohistochemical validation, paraffin sections of hippocampus from seven cases used for microarray analysis, six samples from cases of MTS not included in the microarray analysis (who underwent similar clinical and electrophysiological evaluation and surgical resection) and four hippocampal specimens from normal adults who never had seizure activity were obtained from Human Brain Tissue Repository (Human Brain Bank, Department of Neuropathology, NIMHANS). For the sake of uniformity, dorsal hippocampus with characteristic cytological architecture and middle temporal lobe were used for immunohistochemistry.

RNA isolation

Brain tissues were transported on ice immediately after surgery and the tissue was dissected and stored in RNAlater (Qiagen, Valencia, CA) till RNA isolation. 50 mg of tissue from the

spiking and non-spiking zones were used for RNA isolation. The tissues were pulverized in 1 ml of QIAzol lysis reagent (Qiagen, Valencia, CA) using homogenizer. Total RNA extraction and purification was carried out using RNeasy Lipid Tissue Mini kit (QIAGEN, Valencia, CA) as per manufacturer's instructions. The quality and the yield of RNA were analyzed by RNA integrity number (RIN) assay by Agilent's 2100 bioanalyzer (Agilent Technologies, Santa Clara CA).

cDNA synthesis, hybridization and data analysis

Template mRNA from the samples were primed with an oligo dT-T7 primer into dsDNA by MMLV-RT and later amplified linearly by T7 RNA Polymerase using fluorescent linear amplification kit (Agilent Technologies, Santa Clara). Non-spiking zone sample was labeled with Cy3-CTP and the spiking zone sample was labeled with Cy5-CTP. Microarray labeling and hybridization were carried out as previously described [15]. The images were processed with Agilent feature extraction software (AFE 9.5). The data were processed using GeneSpring GX v11.0.2 (Agilent Technologies, Santa Clara). Lowess normalized data was subjected to statistical analysis. T test was done to identify differentially expressed genes in spiking zones as compared against non-spiking regions. A p-value cut-off of 0.05 and a fold value change of 2 was used as a filter to identify significantly expressed genes.

Data submission

The raw data and the processed obtained in this study has been submitted to Gene Expression Omnibus (GEO Accession # GSE25453).

Bioinformatics analysis

Ingenuity pathway analysis (IPA) was employed for construction of functional analysis network. We selected genes based on a p value of < 0.001 and with a fold value change of 1.5 for IPA analysis. This gene set with their corresponding expression values was used as input for pathway analysis using Ingenuity knowledge database. Molecules common between our dataset and Ingenuity's Knowledge Base were considered for network generation by overlaying onto a global molecular network compiled from the data present in Ingenuity's Knowledge Base. Networks from the ingenuity were selected based on the number of molecules overlaid from our data and significance of those networks associated with temporal lobe epilepsy.

Immunohistochemical analysis

A subset of the upregulated molecules were chosen for validation in an independent set of six epilepsy cases, four normal controls and seven cases which were used for microarray analysis. Proteins encoded by *STK31* and *SMARCA4* genes were selected based on their novelty in the context of MTLE and potential biological relevance with the disease. Four micron thick paraffin sections from 10% buffered formalin fixed tissues from hippocampus and temporal lobe from cases of MTS and normal controls were collected.

Immunohistochemical staining of these sections were performed using Vectastatin kit (Vector laboratories, catalog No#PK-6101) following standardized antigen retrieval procedure by microwaving in citrate buffer (p^H 6.0) for 30 minutes. The sections were incubated with primary antibodies for *STK31* (dilution: 1:200, ab71698) and *SMARCA4* (dilution: 1:100, ab91594). After overnight incubation at 4°C, the slides were washed with PBS. The slides were then incubated with appropriate secondary antibodies followed by incubation with vector ABC reagents. The sections were developed by NovaRED peroxidase substrate (Vector laboratories, catalog No#SK-4800) and counter stained with hematoxylin. These labeled tissue sections were reviewed by two neuropathologists. The staining intensity was semiquantitatively scored as negative (0), mild (1+), moderate (2+)

and strong (3+). The distribution of stained cells was scored as 0 (less than 5% of cells staining), 1+ (5–30% of cell staining), 2+ (31–60% of cells staining) and 3+ (greater than 60% of cells staining).

Results and Discussion

Changes in gene expression profile of intractable MTLE were studied by performing two-color whole human genome microarray analysis. Ten brain tissue samples from confirmed cases of intractable MTLE were employed for this study. The workflow adopted in this study is illustrated in Figure 1. We identified 413 genes that were differentially expressed with a p-value cut-off of < 0.05 and fold change cut off of ≥ 2 . A complete list of these genes is provided in supplementary Table 1. A partial list of differentially expressed genes with a fold-change ≥ 2 is provided in Table 2. We also performed unsupervised hierarchical clustering of the differentially expressed genes for all the ten cases using Euclidean distance metric and centroid linkage as parameters for calculation of distance and linkage of gene clusters. Figure 2 shows a heat map of differentially expressed genes.

Genes overexpressed in medial temporal lobe epilepsy

Of the 102 genes that were significantly upregulated, we found several genes that are in agreement with previous studies on epilepsy while the large majority was unique to this study. Some of the salient ones are discussed below.

Known genes identified as associated with MTLE

Previous gene expression profiling studies in MTLE have been carried out on patients as well as on animal models [8,10,13]. Earlier studies have shown that *EPM2AIP1* (*EPM2A* (laforin) interacting protein) is associated with idiopathic generalized epilepsy and febrile seizures. A copy number gain of 3p22.3 region harboring *EPM2AIP1* was observed in 30% of these cases [16]. Even though the function of *EPM2AIP1* is not known, it has been shown to interact with laforin, a gene associated with adolescent progressive myoclonus epilepsy [17]. In this study, *EPM2AIP1* was found to be overexpressed 2-fold in MTLE as compared to controls. *BACH2* (BTB (BR-C, ttk and bab) and CNC (Cap'n'Collar) homology 1, basic leucine zipper transcription factor 2) has been shown to be upregulated in MTLE expression profiling by Arion et al. [8]. *BACH2* is a transcriptional regulator, which is expressed in B lymphoid cells and differentiated neuronal cells. This protein is known to regulate differentiation of precursor neuronal cells by regulating cdk inhibitor, p21 [18]. We observed a 1.7-fold upregulation of *BACH2* in MTLE.

ACTN1 belongs to spectrin superfamily, which is associated with regulation of cell structure. Studies have reported that *ACTN1* induces expansion of astrocytoma cells [19]. *ACTN1* (actinin, alpha 1) has been shown to be downregulated in MTLE [12]. We found a 2-fold downregulation of *ACTN1* in our study, which correlates with the cell loss associated with MTLE. *MAPK1* (mitogen-activated protein kinase 1) is a member of MAP kinase family that is involved in cellular signaling of proliferation and differentiation. MAPK pathway is known to play a key role in survival of neuronal cells. It has been shown that disruption of MAPK pathway leads to neuronal cell death [20]. Expression profiling of MTLE have shown that *MAPK1* is downregulated and our data also recorded a 1.5-fold down regulation [8,12]. *PTPN5* gene encodes brain specific intracellular tyrosine phosphatase that regulates MAPK pathway thereby governing cell survival [21]. Van gassen et al. [11] have shown that *PTPN5* (protein tyrosine phosphatase, non-receptor type 5 (striatum-enriched)) is downregulated in temporal lobe epilepsy with hippocampal sclerosis. We also observed that *PTPN5* is 1.5-fold downregulated in temporal lobe epilepsy. Studies have revealed that *PTPN5* limits the neuronal toxicity of activated p38 *MAPK* and improves

neuronal survival [22]. This correlates with the hippocampal sclerosis associated with the MTLE. Previous investigation on tumor necrosis factor activated cell death in seizure induced rats has shown that neuronal cell death is mediated by signal regulating kinase 1 (*ASK1*) [23]. Protein phosphatase 5 is known to negatively regulate *ASK1* by dephosphorylation [23,24]. Our study has shown that *PPP5c* (Protein phosphatase 5, catalytic subunit) is downregulated 2 fold. Thus we identified many genes that associated with neuronal cell survival to be downregulated, which correlates with severe neuronal loss in Ammon's horn of hippocampus in cases of MTLE.

Novel genes upregulated in medial temporal lobe epilepsy

In this study, we found many genes that were not reported previously in the context of MTLE. A partial list of these genes is provided in Table 2 and a few selected molecules that could serve as potential biomarkers are discussed in greater detail below. *ADAMTS15* encodes for a member of ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family, was found to be significantly perturbed (3-fold overexpressed) in this study. *ADAMTS15* is an extracellular protease which plays roles in cell fusion and cell-cell interactions [25]. The secretory nature of this protein provides the potential for detecting *ADAMTS15* in body fluids such as cerebrospinal fluid. However this needs to be further validated in body fluids in an independent set of samples to test the utility of *ADAMTS15* as potential candidate for diagnostic biomarker. *BMPRI1B* is upregulated 2.7-fold in MTLE in our study. *BMPRI1B* (Bone morphogenetic protein receptor, type 1B) encodes a member of BMP receptor family of transmembrane serine/threonine kinases. Transgenic mice experiments have shown that Bmpr1b mediates BMP signaling on oligodendrocyte lineage commitment [26] thus leading to inhibition of differentiation of neuronal progenitor cells to oligodendroglial cells [27]. Knockout mice experiments have demonstrated that Bmpr1b signaling inhibits the beneficiary effects of Bmpr1b leading to a glial scar [28]. *CLDN11* or Oligodendrocyte-specific protein (*OSP*) was found to be 2.5 fold upregulated in our study. *CLDN11* encodes for a transmembrane protein, which is concentrated in myelin of central nervous system (CNS) and controls oligodendrocytes milieu in CNS by regulating proliferation and migration [29]. Further, *OSP/CLDN11* is associated as an autoantigen in the development of autoimmune demyelinating disease [30].

Downregulated genes in medial temporal lobe epilepsy

SPINK4 (serine protease inhibitor Kazal-type 4 precursor) was downregulated 3-fold in this study. *SPINK4* is a secretory protein, which is known to regulate dopamine and GABA release in the dorsolateral neostriatum by a selective and facilitatory interaction with the postsynaptic dopamine D2 receptor [8,31]. *TRPM6* (transient receptor potential cation channel, subfamily M, member 6) is a member of mammalian transient receptor channel superfamily that has been shown to be associated with hypomagnesemia and with secondary hypocalcemia [32]. *TRPM6* was two fold down regulated in our study. Quantitative PCR studies have shown that *TRPM6* is enriched in brain compared to other members of TRP family. In renal tissues of mice, reduced expression of *TRPM6* mRNA was found to be correlated with hypomagnesaemia [33]. It is also established that rat hippocampal neurons cultured in magnesium free buffer mimicked status epilepticus [32], thus demonstrating the role of magnesium homeostasis in epilepsy. Thus the role of *TRPM6* needs to be further studied to understand the association with epileptogenesis as well as the potential role as an indicator of MTLE. Mouse lacking serotonin receptors such as 5-HT1A receptors exhibit increased seizure activity [34]. In our study, *HTR1F*, which belongs to 5HT1 receptor family, was found to be downregulated 2.6 fold. Further investigation will be needed to elucidate the role of this receptor in the context of MTLE.

Genes associated with subset of neurons and glia

Different cell populations are associated with medial temporal lobe epilepsy. Previous studies have shown that cells such as glia and GABAergic neurons are involved in pathogenesis of epilepsy [8,20,35]. These studies also revealed the association of subset of genes with specific cell types. In our study, we found differential expression of novel genes associated with glial cells (astrocytes and oligodendrocytes) as well as subset of neurons, which include GABAergic neuronal cells.

Glial cells are implicated in pathophysiology of seizures as these cells control intraneuronal potassium and calcium homeostasis, thus associated with the spike-wave discharges [36,37]. Histopathological analysis of cortical tissues of MTLE cases with medial temporal sclerosis have shown nuclear hypertrophy of astrocytes [38]. Also, glial cell signaling such as astrocytes interplay with neurons are shown to contribute in the induction of neuronal death following pilocarpine-induced seizures [35]. *ADAMTS15* (3-fold), *BMPRI1B* (2.7-fold), *CLDN11* (2.5-fold), *PRKAA2* (2-fold) and *CRHR2* (2-fold) are a few of the genes that were overexpressed in our study and also known to be expressed in glial cells. *PRKAA2* (protein kinase, AMP-activated, alpha 2 catalytic subunit) is a catalytic subunit of the AMP-activated protein kinase, which acts as sensor of AMP: ATP changes in the cell. The studies in glioblastoma cell lines has shown that *PRKAA2* over expression in response to hypoxia [38,39]. Hypoxia is a phase in the epileptic seizure, reflecting neuronal ischemia [40] and shrunken eosinophilic neurons in the hippocampus and temporal cortex. *CRHR2* (corticotrophin releasing hormone receptor 2) is another upregulated molecule which is expressed by microglia and astrocytes thus presenting these cell types as targets for corticotrophin releasing hormone [41]. The association of these hormone and its receptors in epilepsy has to be further investigated in the reparative strategy.

We found a significant perturbation of GABA-associated genes. The present study observed an association of four GABAergic gene expression within the epileptic focuses with spike, those include gamma-aminobutyric acid receptor-associated protein (*GABARAP*), gamma-aminobutyric acid (GABA) receptor, rho 2 (*GABRR2*), gamma-aminobutyric acid (GABA) B receptor 2 (*GABBR2*) and gamma-aminobutyric acid (GABA) A receptor, alpha 6 (*GABRA6*). All these genes are downregulated in epileptic focus with a p value of 0.001 and a fold value of 1.5. In addition, another gene which is associated with transport of GABA called solute carrier family-6 (neurotransmitter transporter, GABA), member 11 (*SLC6A11*) are also found to be downregulated in epilepsy. These GABAergic associated genes were identified within a network of genes that were significantly downregulated (Figure 3). This was determined algorithmically by compiling molecules from ingenuity knowledge base with the expression values of the genes from our study. This is in agreement with earlier reports [8,42], which described GABAergic neuronal loss in temporal lobe epilepsy. Since GABAergic neurons are inhibitory in nature, their loss likely leads to disinhibition of excitatory stimuli and subsequent seizure activity.

Immunohistochemical validation of a panel of novel candidate biomarkers for MTLE

Histological evaluation of the routine HE stained sections revealed severe loss of neurons in CA+ zone and hilar area (CA4) and preserved subiculum reflecting medial temporal sclerosis. The temporal lobe sections with spikes revealed various grades of cortical dysplasia. We selected Serine/threonine kinase 31 (*STK31*) as it is a novel marker which has not previously been described to be associated with MTLE. *STK31* codes for a protein kinase with a tudor domain and was 2-fold upregulated in our study with a significant p-value of 0.014. Studies have already reported that increased expression of kinases such as protein kinase C and adenosine kinase are associated with MTLE modulating increased neuronal excitability in multiple ways [43,44]. Recent data has also demonstrated that

treating rats with kinase inhibitors abrogated epileptogenesis and acute seizure activity [45]. Immunohistochemical analysis for STK31 in brain tissue from control cases with no seizure activity revealed lack of expression of STK31 in hippocampus dentate gyrus as well as pyramidal neurons of the Ammon's horn. No labeling was noted in the subiculum, entorhinal cortex or the anterior temporal cortex either in glia or neuronal cell soma (Figure 4A). In resected hippocampectomy specimens from patients with MTLE, however; there was upregulated expression in neuronal soma and nucleus of pyramidal neurons (Figure 4B). In addition, the superficial part of Ammon's horn, close to the alveus, revealed significant dendritic and axonal labeling (Figure 4C) in addition to molecular layer and granule neurons of dentate gyrus. Similarly, in the temporal cortex, variable labeling was noted within the cytoplasm and nucleus of neurons as well as overlying molecular layer and subpial astrocytes in superficial cortex. Further validation on large independent set of samples including CSF is required to confirm its potential to as a biomarker for MTLE.

SMARCA4 is downregulated 2.3-fold (p-value: 0.00023) in medial temporal lobe with seizure discharges (spike zones) compared to non-spike zone. The protein encoded by this gene is a member of the SWI/SNF family of proteins and members of this family have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure [46]. Knockdown of *SMARCA4* leads to inhibition of proliferation of cells. Transcriptional activities of neurogenin and neuroD are regulated by *SMARCA4*, thus making it essential for neural differentiation. *SMARCA4* is also associated with senescence leading to a reduced expression of stemness-related genes [47]. We validated *SMARCA4* by immunohistochemistry in an independent set of samples as well as in the samples that were analyzed for microarray. Figure 5 shows the staining pattern of *SMARCA4*. Strong labeling was noted within the cytoplasm of neurons in dentate gyrus and variable positivity in pyramidal neurons of Ammon's horn and temporal cortex in controls (Figure 5A, B). Scattered neurons were also highlighted in subiculum particularly in the lower layers. In contrast, labeling was absent in hippocampal pyramidal neurons and dentate gyrus granule neurons in cases of epilepsy (Figure 5C, D). A few scattered glial cells expressed *SMARCA4* unlike neurons in temporal cortex (Figure 5D), considerably down regulated compared to controls. The variable immunohistochemical concordance in cell type is probably reflection of differing vulnerabilities of the neurons and glia to seizure discharges.

Conclusions

We have employed DNA microarrays to discover a set of genes that were differentially expressed in epileptic foci of MTLE. We identified a set of novel transcripts that are not described in the context of human MTLE. We also validated *STK31* and *SMARCA4* expression profile in an independent set of samples for their potential as candidate diagnostic/prognostic biomarker in intractable MTLE and an insight to pathobiology. In accordance with previous reports, we also found upregulation of astrocyte-associated genes. Additionally, we observed a subset of GABAergic neuron associated genes that were significantly downregulated. There is further need to evaluate the effect of differential expression of these novel genes in epileptogenesis, clinical progression and refractoriness to therapeutic regimen in cases of medial temporal lobe epilepsy and their usefulness as biomarkers in the clinical management.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The present work was supported by a research grant “DBT Programme Support on Neuroproteomics of Neurological Disorders” to the Institute of Bioinformatics and National Institute of Mental Health and Neurosciences, funded by Department of Biotechnology, Government of India. Human brain tissues for the study were obtained from the Human Brain Tissue Repository (Brain Bank) Department of Neuropathology, National Institute of Mental Health and Neuro Sciences, Bangalore, India. A. P. is supported in part by an NIH roadmap grant for Technology Centers of Networks and Pathways (U54RR020839).

Abbreviation

MTLE	Medial temporal lobe epilepsy
HPRD	Human Protein Reference Database
GEO	Gene Expression Omnibus

References

1. Atlas: Epilepsy Care in the World. World Health Organization; 2005.
2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. *N Engl J Med*. 2000; 342:314–319. [PubMed: 10660394]
3. Schmidt D. Two antiepileptic drugs for intractable epilepsy with complex-partial seizures. *J Neurol Neurosurg Psychiatry*. 1982; 45:1119–1124. [PubMed: 6819340]
4. Brodie MJ, Dichter MA. Antiepileptic drugs. *N Engl J Med*. 1996; 334:168–175. [PubMed: 8531974]
5. Williamson PD, French JA, Thadani VM, Kim JH, Novelly RA, et al. Characteristics of medial temporal lobe epilepsy: II. Interictal and ictal scalp electroencephalography, neuropsychological testing, neuroimaging, surgical results, and pathology. *Ann Neurol*. 1993; 34:781–787. [PubMed: 8250526]
6. Blumcke I, Beck H, Lie AA, Wiestler OD. Molecular neuropathology of human mesial temporal lobe epilepsy. *Epilepsy Res*. 1999; 36:205–223. [PubMed: 10515166]
7. Becker AJ, Chen J, Paus S, Normann S, Beck H, et al. Transcriptional profiling in human epilepsy: expression array and single cell real-time qRT-PCR analysis reveal distinct cellular gene regulation. *Neuroreport*. 2002; 13:1327–1333. [PubMed: 12151797]
8. Arion D, Sabatini M, Unger T, Pastor J, Alonso-Nanclares L, et al. Correlation of transcriptome profile with electrical activity in temporal lobe epilepsy. *Neurobiol Dis*. 2006; 22:374–387. [PubMed: 16480884]
9. Xiao Z, Gong Y, Wang XF, Xiao F, Xi ZQ, et al. Altered expression of synaptotagmin I in temporal lobe tissue of patients with refractory epilepsy. *J Mol Neurosci*. 2009; 38:193–200. [PubMed: 18779938]
10. Jamali S, Bartolomei F, Robaglia-Schlupp A, Massacrier A, Peragut JC, et al. Large-scale expression study of human mesial temporal lobe epilepsy: evidence for dysregulation of the neurotransmission and complement systems in the entorhinal cortex. *Brain*. 2006; 129:625–641. [PubMed: 16399808]
11. van Gassen KL, de Wit M, Koerkamp MJ, Rensen MG, van Rijen PC, et al. Possible role of the innate immunity in temporal lobe epilepsy. *Epilepsia*. 2008; 49:1055–1065. [PubMed: 18076643]
12. Lee TS, Mane S, Eid T, Zhao H, Lin A, et al. Gene expression in temporal lobe epilepsy is consistent with increased release of glutamate by astrocytes. *Mol Med*. 2007; 13:1–13. [PubMed: 17515952]
13. Lauren HB, Lopez-Picon FR, Brandt AM, Rios-Rojas CJ, Holopainen IE. Transcriptome analysis of the hippocampal CA1 pyramidal cell region after kainic acid-induced status epilepticus in juvenile rats. *PLoS One*. 2010; 5:e10733. [PubMed: 20505763]
14. Mirza N, Vasieva O, Marson AG, Pirmohamed M. Exploring the genomic basis of pharmacoresistance in epilepsy: an integrative analysis of large-scale gene expression profiling

- studies on brain tissue from epilepsy surgery. *Hum Mol Genet.* 2011; 20:4381–4394. [PubMed: 21852245]
15. Kashyap MK, Marimuthu A, Kishore CJ, Peri S, Keerthikumar S, et al. Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers. *Cancer Biol Ther.* 2009; 8:36–46. [PubMed: 18981721]
 16. Kim HS, Yim SV, Jung KH, Zheng LT, Kim YH, et al. Altered DNA copy number in patients with different seizure disorder type: by array-CGH. *Brain Dev.* 2007; 29:639–643. [PubMed: 17573221]
 17. Ianzano L, Zhao XC, Minassian BA, Scherer SW. Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product. *Genomics.* 2003; 81:579–587. [PubMed: 12782127]
 18. Shim KS, Rosner M, Freilinger A, Lubec G, Hengstschlager M. Bach2 is involved in neuronal differentiation of N1E-115 neuroblastoma cells. *Exp Cell Res.* 2006; 312:2264–2278. [PubMed: 16631738]
 19. Quick Q, Skalli O. Alpha-actinin 1 and alpha-actinin 4: contrasting roles in the survival, motility, and RhoA signaling of astrocytoma cells. *Exp Cell Res.* 2010; 316:1137–1147. [PubMed: 20156433]
 20. Choi YS, Lin SL, Lee B, Kurup P, Cho HY, et al. Status epilepticus-induced somatostatinergic hilar interneuron degeneration is regulated by striatal enriched protein tyrosine phosphatase. *J Neurosci.* 2007; 27:2999–3009. [PubMed: 17360923]
 21. Braithwaite SP, Xu J, Leung J, Urfer R, Nikolich K, et al. Expression and function of striatal enriched protein tyrosine phosphatase is profoundly altered in cerebral ischemia. *Eur J Neurosci.* 2008; 27:2444–2452. [PubMed: 18445231]
 22. Poddar R, Deb I, Mukherjee S, Paul S. NR2B-NMDA receptor mediated modulation of the tyrosine phosphatase STEP regulates glutamate induced neuronal cell death. *J Neurochem.* 2010; 115:1350–1362. [PubMed: 21029094]
 23. Shinoda S, Skradski SL, Araki T, Schindler CK, Meller R, et al. Formation of a tumour necrosis factor receptor 1 molecular scaffolding complex and activation of apoptosis signal-regulating kinase 1 during seizure-induced neuronal death. *Eur J Neurosci.* 2003; 17:2065–2076. [PubMed: 12786973]
 24. Morita K, Saitoh M, Tobiume K, Matsuura H, Enomoto S, et al. Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress. *EMBO J.* 2001; 20:6028–6036. [PubMed: 11689443]
 25. Vilorio CG, Obaya AJ, Moncada-Pazos A, Llamazares M, Astudillo A, et al. Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. *Cancer Res.* 2009; 69:4926–4934. [PubMed: 19458070]
 26. Samanta J, Burke GM, McGuire T, Pisarek AJ, Mukhopadhyay A, et al. BMPRIa signaling determines numbers of oligodendrocytes and calbindin-expressing interneurons in the cortex. *J Neurosci.* 2007; 27:7397–7407. [PubMed: 17626200]
 27. Samanta J, Kessler JA. Interactions between ID and OLIG proteins mediate the inhibitory effects of BMP4 on oligodendroglial differentiation. *Development.* 2004; 131:4131–4142. [PubMed: 15280210]
 28. Sahni V, Mukhopadhyay A, Tysseling V, Hebert A, Birch D, et al. BMPRIa and BMPRIb signaling exert opposing effects on gliosis after spinal cord injury. *J Neurosci.* 2010; 30:1839–1855. [PubMed: 20130193]
 29. Bronstein JM, Tiwari-Woodruff S, Buznikov AG, Stevens DB. Involvement of OSP/claudin-11 in oligodendrocyte membrane interactions: role in biology and disease. *J Neurosci Res.* 2000; 59:706–711. [PubMed: 10700007]
 30. Aslam M, Kalluri SR, Cepok S, Kraus V, Buck D, et al. The antibody response to oligodendrocyte specific protein in multiple sclerosis. *J Neuroimmunol.* 2010; 221:81–86. [PubMed: 20236710]
 31. Rimondini R, O'Connor WT, Sillard R, Mutt V, Ungerstedt U, et al. The secretory trypsin inhibitor like-peptide, PEC-60 increases dopamine D2 receptor agonist induced inhibition of GABA release in the dorsolateral neostriatum of the awake freely moving rat. An in vivo microdialysis study. *Regul Pept.* 1996; 61:111–117. [PubMed: 8852813]

32. Schlingmann KP, Weber S, Peters M, Niemann Nejsun L, Vitzthum H, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. *Nat Genet.* 2002; 31:166–170. [PubMed: 12032568]
33. Jiang SP, Wu YM, Guo SE, Lv ZQ. Decreased renal mRNA expression of TRPM6 is associated with hypomagnesemia in C57BL/6 asthmatic mice. *Eur Rev Med Pharmacol Sci.* 2010; 14:935–940. [PubMed: 21284342]
34. Bagdy G, Kecskemeti V, Riba P, Jakus R. Serotonin and epilepsy. *J Neurochem.* 2007; 100:857–873. [PubMed: 17212700]
35. Aronica E, Gorter JA. Gene expression profile in temporal lobe epilepsy. *Neuroscientist.* 2007; 13:100–108. [PubMed: 17404370]
36. Tashiro A, Goldberg J, Yuste R. Calcium oscillations in neocortical astrocytes under epileptiform conditions. *J Neurobiol.* 2002; 50:45–55. [PubMed: 11748632]
37. Amzica F, Massimini M, Manfredi A. Spatial buffering during slow and paroxysmal sleep oscillations in cortical networks of glial cells in vivo. *J Neurosci.* 2002; 22:1042–1053. [PubMed: 11826133]
38. Kendal C, Everall I, Polkey C, Al-Sarraj S. Glial cell changes in the white matter in temporal lobe epilepsy. *Epilepsy Res.* 1999; 36:43–51. [PubMed: 10463849]
39. Carrero-Valenzuela RD, Quan F, Lightowlers R, Kennaway NG, Litt M, et al. Human cytochrome c oxidase subunit VIb: characterization and mapping of a multigene family. *Gene.* 1991; 102:229–236. [PubMed: 1651883]
40. Geneslaw AS, Zhao M, Ma H, Schwartz TH. Tissue hypoxia correlates with intensity of interictal spikes. *J Cereb Blood Flow Metab.* 2011; 31:1394–1402. [PubMed: 21343943]
41. Stevens SL, Shaw TE, Dykhuizen E, Lessov NS, Hill JK, et al. Reduced cerebral injury in CRH-R1 deficient mice after focal ischemia: a potential link to microglia and astrocytes that express CRH-R1. *J Cereb Blood Flow Metab.* 2003; 23:1151–1159. [PubMed: 14526225]
42. Knopp A, Frahm C, Fidzinski P, Witte OW, Behr J. Loss of GABAergic neurons in the subiculum and its functional implications in temporal lobe epilepsy. *Brain.* 2008; 131:1516–1527. [PubMed: 18504292]
43. Kim YS, Choi MY, Kim YH, Jeon BT, Lee DH, et al. Protein kinase Cdelta is associated with 14-3-3 phosphorylation in seizure-induced neuronal death. *Epilepsy Res.* 2010; 92:30–40. [PubMed: 20813501]
44. Boison D. Adenosine kinase, epilepsy and stroke: mechanisms and therapies. *Trends Pharmacol Sci.* 2006; 27:652–658. [PubMed: 17056128]
45. Gajda Z, Torok R, Horvath Z, Szantai-Kis C, Orfi L, et al. inhibitor as a potential candidate for epilepsy treatment. *Epilepsia.* 2011; 52:579–588. [PubMed: 21371019]
46. Kazantseva A, Sepp M, Kazantseva J, Sadam H, Pruunsild P, et al. N-terminally truncated BAF57 isoforms contribute to the diversity of SWI/SNF complexes in neurons. *J Neurochem.* 2009; 109:807–818. [PubMed: 19245665]
47. Alessio N, Squillaro T, Cipollaro M, Bagella L, Giordano A, et al. The BRG1 ATPase of chromatin remodeling complexes is involved in modulation of mesenchymal stem cell senescence through RB-P53 pathways. *Oncogene.* 2010; 29:5452–5463. [PubMed: 20697355]

Figure 1. Workflow of transcriptomic studies for MTLE

A two color DNA microarray analysis based approach employed for the transcriptome profiling of spiking (seizure) against non-spiking (non-seizure) zones of MTLE. An unsupervised hierarchical clustering was performed on differentially expressed molecules and a selected set of novel molecules were validated by IHC.

Figure 2. Heat map of differentially expressed genes in MTLE

A heat map was generated by performing unsupervised hierarchical clustering of 413 differentially expressed genes with a p value cut-off of <0.05 and a fold value cut-off of 2. Euclidean distance and centroid linkage were used for generating the hierarchical cluster (A). A heat map of a selected set of differentially regulated genes is shown in B.

Figure 3. A statistically significant network identified by pathway analysis
The network was overlaid with GABAergic pathway and the color code of molecules represents the expression levels wherein red shows upregulated and green indicates downregulation.

Figure 4. Overexpression of STK31 in MTLE

Pyramidal neurons of temporal cortex (B) (Obj x 20) and Ammon's horn (C) (Obj x 10) reveals strong, cytoplasmic and nuclear labeling from a case of hippocampal sclerosis in contrast to lack of expression in normal control hippocampus (A) (Obj x 10). Note the dendritic labeling in pyramidal neurons and axonal labeling in the alveus (C).

Figure 5. Downregulation of SMARCA4 in MTL

A–B: Control hippocampus showing diffuse labeling of dentate gyrus granule neurons (A) (Obj x 40), and pyramidal neurons of Ammon's horn (B) (Obj x 40). C–D: Hippocampus from a case of mesial temporal sclerosis showing absent expression in dentate granule neuron (C) (Obj x 40) is compared to control. Light cytoplasmic labeling of pyramidal neurons and nuclear labeling of scattered glial cells seen in temporal cortex (D) (Obj x 20), markedly downregulated compared to controls.

Table 1
Clinical and labeling details of the samples employed for transcriptomic profiling of MTLE.

Sl. No	Sample ID	Age/Sex	Tissues used	Surface electrocorticography during surgery	Cy3/Cy5	Diagnosis
1.	08/HBTR/T205	25/F	Dorsal Hippocampus Head of Hippocampus	No spikes With spikes	Cy3 Cy5	mTLE
2.	Bx124	22/M	Tail of hippocampus Head of hippocampus	No spikes With spikes	Cy3 Cy5	mTLE
3.	08/HBTR/T167	16/M	Tail of hippocampus Head of hippocampus	No spikes With spikes	Cy3 Cy5	mTLE
4.	08/HBTR/T171	32/F	Middle temporal gyrus Superior temporal gyrus	No spikes With spikes	Cy3 Cy5	mTLE
5.	08/HBTR/T172	37/F	Middle temporal gyrus Superior temporal gyrus	No spikes With spikes	Cy3 Cy5	mTLE
6.	08/HBTR/T173	16/M	Head of hippocampus Body of hippocampus	No spikes With spikes	Cy3 Cy5	mTLE
7.	08/HBTR/T193	35/F	Head of hippocampus Body of hippocampus	No spikes With spikes	Cy3 Cy5	mTLE
8.	08/HBTR/T194	27/M	Superior temporal gyrus Inferior temporal gyrus	No spikes With spikes	Cy3 Cy5	mTLE
9	08/HBTR/T196	37/F	Posterior temporal gyrus Anterior temporal gyrus	No spikes With spikes	Cy3 Cy5	mTLE
10	08/HBTR/T178	18/M	Hippocampus Temporal gyrus	No spikes With spikes	Cy3 Cy5	mTLE

Table 2

A partial list of differentially expressed genes in MTE.

SL No	Gene Symbol	Protein	Features	Fold change	p-value
1	<i>CLEC18A</i>	C-type lectin domain family 18, member A	Localized extracellularly,	+4.3	0.0000018
2	<i>ARL11</i>	ADP-ribosylation factor-like 1	Play a role in caspase dependant apoptosis	+3.9	0.000087
3	<i>GALNT5</i>	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5	Transmembrane protein shown to be expressed in body fluids such as tears	+3.1	0.001
4	<i>ADAMTS15</i>	ADAM metalloproteinase with thrombospondin type 1 motif, 15	Known to be localized extracellularly could detect in body fluids A serine/threonine kinase with primary	+3.0	0.00019
5	<i>BMPRII</i>	Bone morphogenetic protein receptor, type I	localization of plasma membrane. It also has transmembrane domain.	+2.7	0.0025
6	<i>CLDN11</i>	Claudin 11	An integral membrane protein and a marker for oligo dendrocytes	+2.5	0.021
7	<i>SC4MOL</i>	Sterol-C4-methyl oxidase-like	A transmembrane protein localized to endoplasmic reticulum and also involved in lipid synthesis	+2.2	0.0037
8	<i>IL20RB</i>	Interleukin 20 receptor beta	A heterodimeric receptor for interleukin-20, which is associated with inflammation	+2.2	0.00024
9	<i>PPBP</i>	Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)	Localized extracellularly and a chemo attractant.	+2.2	0.02
10	<i>STK31</i>	Serine/threonine kinase 31	A kinase with a tudor domain.	+2.0	0.014
11	<i>SPINK4</i>	Serine peptidase inhibitor, Kazal type	Localized extracellularly and known to regulate GABA release	-3.1	0.000036
12	<i>TYMP</i>	Thymidine phosphorylase	Localized extracellularly and known to be secreted in body fluids such as tears.	-2.9	0.00013
13	<i>STOML3</i>	Stomatin (EPB72)-like 3	A transmembrane protein localized to plasma membrane	-2.7	0.0041
14	<i>TPTE2</i>	Transmembrane phosphoinositide 3-phosphatase and tensin homolog	A membrane associated phosphoinositide 3-phosphatase	-2.7	0.000069
15	<i>SMARCA4</i>	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Transcription regulator and associated with neurogenesis	-2.3	0.00023